1. Brusselle, G. and K. Bracke, Targeting immune pathways for therapy in asthma and chronic obstructive pulmonary disease. Ann Am Thorac Soc, 2014. 11 Suppl 5: p. S322-8.
2. Wenzel, S.E., et al., Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med, 1997. 156(3 Pt 1):p. 737-43.
3. Woodruff, P.G., et al., Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol, 2001. 108(5): p. 753-8.
4. Gold, D.R. and A.L. Fuhlbrigge, Inhaled corticosteroids for young children with wheezing. N Engl J Med, 2006. 354(19): p. 2058-60.
5. Hastie, A.T., et al., Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol, 2013. 132(1): p. 72-80.
6. Kawaguchi, M., et al., Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. J Immunol, 2001. 167(8): p. 4430-5.
7. Kawaguchi, M., L.F. Onuchic, and S.K. Huang, Activation of extracellular signal- regulated kinase (ERK)1/2, but not p38 and c-Jun N-terminal kinase, is involved in signaling of a novel cytokine, ML-1. J Biol Chem, 2002. 277(18): p. 15229-32.
8. Kawaguchi, M., et al., Induction of C-X-C chemokines, growth-related oncogene alpha expression, and epithelial cell-derived neutrophil-activating protein-78 by ML-1 (interleukin-17F) involves activation of Raf1-mitogen-activated protein kinase kinase-extracellular signal-regulated kinase 1/2 pathway. J Pharmacol Exp Ther, 2003. 307(3): p. 1213-20.
9. Oda, N., et al., Interleukin-17F induces pulmonary neutrophilia and amplifies antigen-induced allergic response. Am J Respir Crit Care Med, 2005. 171(1): p. 12-8.
10. Kawaguchi, M., et al., IL-17F sequence variant (His161Arg) is associated with protection against asthma anda antagonizes wild-type IL-17F activity. J Allergy Clin Immunol, 2006. 117(4): p.795-801.
11. Al-Ramli, W., et al., T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol, 2009. 123(5): p. 1185-7.
12. Chang, Y., et al., CD8 positive T cells express IL-17 in patients with chronic obstructive pulmonary disease. Respir Res, 2011. 12: p. 43.
13. Kawaguchi, M., et al., IL-17F sequence variant (His161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol, 2006. 117(4): p. 795-801.
14. Elias, J.A., et al., Cytokine- and virus-stimulated airway smooth muscle cells produce IL-11 and other IL-6-type cytokines. Am J Physiol, 1997. 273(3 Pt 1): p. L648-55.
15. Perry, M.M., et al., Airway smooth muscle hyperproliferation is regulated by microRNA-221 in severe asthma. Am J Respir Cell Mol Biol, 2014. 50(1): p. 7- 17.
16. Chang, Y., et al., TH17 cytokines induce human airway smooth muscle cell migration. J Allergy Clin Immunol, 2011. 127(4): p. 1046-53.e1-2.
17. Rincon, M. and C.G. Irvin, Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci, 2012. 8(9): p. 1281-90.
18. Dixon, A.E., et al., Lower airway disease in asthmatics with and without rhinitis. Lung, 2008. 186(6): p. 361-8.
19. Dixon, A.E., et al., Effect of obesity on clinical presentation and response to treatment in asthma. J Asthma, 2006. 43(7): p. 553-8.
20. Neveu, W.A., et al., IL-6 is required for airway mucus production induced by inhaled fungal allergens. J Immunol, 2009. 183(3): p. 1732-8.
21. O'Brien, R.L., C.L. Roark, and W.K. Born, IL-17-producing gammadelta T cells. Eur J Immunol, 2009. 39(3): p. 662-6.
22. Ciric, B., et al., IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol, 2009. 182(9): p. 5296-305.
23. Bettelli, E., et al., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 2006. 441(7090): p. 235- 8.
24. Ghoreschi, K., et al., Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature, 2010. 467(7318): p. 967-71.
25. Dey, N., et al., TAK1 regulates NF-KappaB and AP-1 activation in airway epithelial cells following RSV infection. Virology, 2011. 418(2): p. 93-101.
26. Yun, Y.P., et al., Induction of nuclear factor-kappaB activation through TAK1 and NIK by diesel exhaust particles in L2 cell lines. Toxicol Lett, 2005. 155(2): p. 337- 42.
27. Goleva, E., et al., The effects of airway microbiome on corticosteroid responsiveness in asthma. Am J Respir Crit Care Med, 2013. 188(10): p. 1193- 201.
28. Ordonez, CL., et al., Increased Neutrophil Numbers and IL-8 Levels in Airway Secretions in Acute Severe Asthma. Am J Respir Crit Care Med, 2000. 161(4):1185-90.
29. Stanescu, D., et al., Airways obstruction, chronic expectoration, and rapid delicline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax, 1996. 51(3):267-71.
30. Saetta, M., et al., Inflammatory Cells in the Bronchial Glands of Smokers with Chronic Bronchitis. Am J Respir Crit Care Med, 1997. 156(5):1633-9.
31. Henness, S., et al., IL-17A acts via p38 MAPK to increase stability of TNF-alpha- induced IL-8 mRNA in human ASM. Am J Physiol Lung Cell Mol Physiol, 2006. 290(6): p. L1283-90.
32. Pera, T., et al., Role for TAK1 in cigarette smoke-induced proinflammatory signaling and IL-8 release by human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol, 2012. 303(3): p. L272-8.
33. Watson, M.L., et al., Interleukin 8 and monocyte chemoattractant protein 1 production by cultured human airway smooth muscle cells. Cytokine, 1998. 10(5): p. 346-52.
34. Ota, K., et al., Potential involvement of IL-17F in asthma. J Immunol Res, 2014. 2014: p. 602846.
35. Shao, W. and J. Zeitlinger, Paused RNA polymerase II inhibits new transcriptional initiation. Nat Genet, 2017. 49(7): p. 1045-1051.
36. Yamaguchi, Y., et al., NELF, a multisubunit complex containing RD, cooperates with DISF to repress RNA polymerase 2 elongation. Cell, 1999. 97(1):41-51.
37. Jang, M.K., et al., The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell, 2005. 19(4): p. 523-34.
38. Zhou, M., et al., Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol Cell Biol, 2000. 20(14): p. 5077-86.
39. Luecke, H.F. and K.R. Yamamoto, The glucocorticoid receptor blocks P-TEFb recruitment by NFkappaB to effect promoter-specific transcriptional repression. Genes Dev, 2005. 19(9): p. 1116-27.
40. Li, L.L., et al., Positive transcription elongation factor b (P-TEFb) contributes to dengue virus-stimulated induction of interleukin-8 (IL-8). Cell Microbiol, 2010. 12(11): p. 1589-603.
41. Barboric, M., et al., NF-kB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase 2. Mol Cell, 2001. 8(2):327-37.
42. Tian, B., et al., CDK9-dependent transcriptional elongation in the innate interferon-stimulated gene response to respiratory syncytial virus infection in airway epithelial cells. J Virol, 2013. 87(12): p. 7075-92.
43. Tian, B., et al., BRD4 Couples NF-kappaB/RelA with Airway Inflammation and the IRF-RIG-I Amplification Loop in Respiratory Syncytial Virus Infection. J Virol, 2017. 91(6).
44. Khan, Y.M., et al., Brd4 is essential for IL-1beta-induced inflammation in human airway epithelial cells. PLoS One, 2014. 9(4): p. e95051.
45. Perry, M.M., et al., BET bromodomains regulate transforming growth factor-beta- induced proliferation and cytokine release in asthmatic airway smooth muscle. J Biol Chem, 2015. 290(14): p. 9111-21.
46. Clifford, R.L., et al., CXCL8 histone H3 acetylation is dysfunctional in airway smooth muscle in asthma: regulation by BET. Am J Physiol Lung Cell Mol Physiol, 2015. 308(9): p. L962-72.
47. Cheung, K., et al., BET N-terminal bromodomain inhibition selectively blocks Th17 cell differentiation and ameliorates colitis in mice. Proc Natl Acad Sci U S A, 2017. 114(11): p. 2952-2957.
48. Mele, D.A., et al., BET bromodomain inhibition suppresses TH17-mediated pathology. J Exp Med, 2013. 210(11): p. 2181-90.
49. Kim, J., et al., Role of NF-kappa B in cytokine production induced from human airway epithelial cells by rhinovirus infection. J Immunol, 2000. 165(6): p. 3384- 92.
50. Cormet-Boyaka, E., et al., An NF-kappaB-independent and Erk1/2-dependent mechanism controls CXCL8/IL-8 responses of airway epithelial cells to cadmium. Toxicol Sci, 2012. 125(2): p. 418-29.
51. Mirsaeidi, M., et al., Hospital costs in the US for pulmonary mycobacterial diseases. Int J Mycobacteriol, 2015. 4(3): p. 217-221.
52. Marras, T.K., et al., Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003. Thorax, 2007. 62(8): p. 661-6.
53. Reich, J.M. and R.E. Johnson, Mycobacterium avium complex pulmonary disease. Incidence, presentation, and response to therapy in a community setting. Am Rev Respir Dis, 1991. 143(6): p. 1381-5.
54. Prince, D.S., et al., Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med, 1989. 321(13): p. 863-8.
55. Knowles, M.R., M. Zariwala, and M. Leigh, Primary Ciliary Dyskinesia. Clin Chest Med, 2016. 37(3): p. 449-61.
56. Martiniano, S.L., J.A. Nick, and C.L. Daley, Nontuberculous Mycobacterial Infections in Cystic Fibrosis. Clin Chest Med, 2016. 37(1): p. 83-96.
57. Szymanski, E.P., et al., Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease. Am J Respir Crit Care Med, 2015. 192(5): p. 618-28.
58. Matsuyama, M., et al., Role of Th1/Th17 balance regulated by T-bet in a mouse model of Mycobacterium avium complex disease. J Immunol, 2014. 192(4): p. 1707-17.
59. Matsuyama, M., et al., Overexpression of RORgammat Enhances Pulmonary Inflammation after Infection with Mycobacterium Avium. PLoS One, 2016. 11(1): p. e0147064.
60. Matsuyama, M., et al., Transcriptional Response of Respiratory Epithelium to Nontuberculous Mycobacteria. Am J Respir Cell Mol Biol, 2018. 58(2): p. 241- 252.
61. Zhao, H., et al., The role of nuclear factor-erythroid 2 related factor 2 (Nrf-2) in the protection against lung injury. Am J Physiol Lung Cell Mol Physiol, 2017. 312(2): p. L155-L162.
62. Zhou, Y., et al., The Bach Family of Transcription Factors: A Comprehensive Review. Clin Rev Allergy Immunol, 2016. 50(3): p. 345-56.
63. Williams, M.A., et al., Disruption of the transcription factor Nrf2 promotes pro- oxidative dendritic cells that stimulate Th2-like immunoresponsiveness upon activation by ambient particulate matter. J Immunol, 2008. 181(7): p. 4545-59.
64. Thimmulappa, R.K., et al., Nrf2-dependent protection from LPS induced inflammatory response and mortality by CDDO-Imidazolide. Biochem Biophys Res Commun, 2006. 351(4): p. 883-9.
65. Chang, A.L., et al., Redox regulation of mitophagy in the lung during murine Staphylococcus aureus sepsis. Free Radic Biol Med, 2015. 78: p. 179-89.
66. Athale, J., et al., Nrf2 promotes alveolar mitochondrial biogenesis and resolution of lung injury in Staphylococcus aureus pneumonia in mice. Free Radic Biol Med, 2012. 53(8): p. 1584-94.
67. Reddy, N.M., et al., Innate immunity against bacterial infection following hyperoxia exposure is impaired in NRF2-deficient mice. J Immunol, 2009. 183(7): p. 4601-8.
68. Gomez, J.C., et al., Nrf2 Modulates Host Defense during Streptococcus pneumoniae Pneumonia in Mice. J Immunol, 2016. 197(7): p. 2864-79.
69. Chinta, K.C., et al., Microanatomic Distribution of Myeloid Heme Oxygenase-1 Protects against Free Radical-Mediated Immunopathology in Human Tuberculosis. Cell Rep, 2018. 25(7): p. 1938-1952 e5.
70. Rothchild, A.C., et al., Alveolar macrophages generate a noncanonical NRF2- driven transcriptional response to Mycobacterium tuberculosis in vivo. Sci Immunol, 2019. 4(37).
71. Sykiotis, G.P. and D. Bohmann, Stress-activated cap'n'collar transcription factors in aging and human disease. Sci Signal, 2010. 3(112): p. re3.
72. Deramaudt, T.B., C. Dill, and M. Bonay, Regulation of oxidative stress by Nrf2 in the pathophysiology of infectious diseases. Med Mal Infect, 2013. 43(3): p. 100- 7.
73. Amaral, E.P., et al., N-acetyl-cysteine exhibits potent anti-mycobacterial activity in addition to its known anti-oxidative functions. BMC Microbiol, 2016. 16(1): p. 251.
74. Harada, N., et al., Nrf2 regulates ferroportin 1-mediated iron efflux and counteracts lipopolysaccharide-induced ferroportin 1 mRNA suppression in macrophages. Arch Biochem Biophys, 2011. 508(1): p. 101-9.
75. Zwilling, B.S., et al., Role of iron in Nramp1-mediated inhibition of mycobacterial growth. Infect Immun, 1999. 67(3): p. 1386-92.
76. Kuhn, D.E., et al., Differential iron transport into phagosomes isolated from the RAW264.7 macrophage cell lines transfected with Nramp1Gly169 or Nramp1Asp169. J Leukoc Biol, 1999. 66(1): p. 113-9.
77. Goswami, T., et al., Natural-resistance-associated macrophage protein 1 is an H+/bivalent cation antiporter. Biochem J, 2001. 354(Pt 3): p. 511-9.
78. Gomes, M.S. and R. Appelberg, Evidence for a link between iron metabolism and Nramp1 gene function in innate resistance against Mycobacterium avium. Immunology, 1998. 95(2): p. 165-8.
79. Barton, C.H., et al., Nramp1: a link between intracellular iron transport and innate resistance to intracellular pathogens. J Leukoc Biol, 1999. 66(5): p. 757- 62.
80. Atkinson, P.G. and C.H. Barton, High level expression of Nramp1G169 in RAW264.7 cell transfectants: analysis of intracellular iron transport. Immunology, 1999. 96(4): p. 656-62.
81. Jabado, N., et al., Natural resistance to intracellular infections: natural resistance-associated macrophage protein 1 (Nramp1) functions as a pH- dependent manganese transporter at the phagosomal membrane. J Exp Med, 2000. 192(9): p. 1237-48.
82. Soe-Lin, S., et al., Nramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo. Proc Natl Acad Sci U S A, 2009. 106(14): p. 5960-5.
83. Blackwell, J.M., et al., SLC11A1 (formerly NRAMP1) and disease resistance. Cell Microbiol, 2001. 3(12): p. 773-84.
84. Valdez, Y., et al., Nramp1 drives an accelerated inflammatory response during Salmonella-induced colitis in mice. Cell Microbiol, 2009. 11(2): p. 351-62.
85. Denis, M., et al., Pleiotropic effects of the Bcg gene: III. Respiratory burst in Bcg- congenic macrophages. Clin Exp Immunol, 1988. 73(3): p. 370-5.
86. Frehel, C., et al., Effect of Nramp1 on bacterial replication and on maturation of Mycobacterium avium-containing phagosomes in bone marrow-derived mouse macrophages. Cell Microbiol, 2002. 4(8): p. 541-56.
87. Blackwell, J.M., et al., Divalent cation transport and susceptibility to infectious and autoimmune disease: continuation of the Ity/Lsh/Bcg/Nramp1/Slc11a1 gene story. Immunol Lett, 2003. 85(2): p. 197-203.
88. Vidal, S., et al., The Ity/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene. J Exp Med, 1995. 182(3): p. 655-66.
89. Koh, W.J., et al., NRAMP1 gene polymorphism and susceptibility to nontuberculous mycobacterial lung diseases. Chest, 2005. 128(1): p. 94-101.
90. Tanaka, G., et al., Pulmonary Mycobacterium avium complex infection: association with NRAMP1 polymorphisms. Eur Respir J, 2007. 30(1): p. 90-6.
91. Itoh, K., et al., An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun, 1997. 236(2): p. 313-22.
92. Surolia, R., et al., Attenuated heme oxygenase-1 responses predispose the elderly to pulmonary nontuberculous mycobacterial infections. Am J Physiol Lung Cell Mol Physiol, 2016. 311(5): p. L928-L940.
論文の公開元へ
